Grifols Management

Management criteria checks 2/4

Grifols' CEO is Nacho Abia Buenache, appointed in Apr 2024, has a tenure of less than a year. directly owns 0.014% of the company’s shares, worth €942.54K. The average tenure of the management team and the board of directors is 6.8 years and 7 years respectively.

Key information

Nacho Abia Buenache

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.01%
Management average tenure	6.8yrs
Board average tenure	7yrs

Recent management updates

Recent updates

CEO

Nacho Abia Buenache (56 yo)

less than a year

Tenure

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% € 942.5k
Alfredo Guerra	CFO & VP	17.8yrs	no data	no data
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	no data	no data
Nuria Lapeña	VP of Corporate Treasury	no data	no data	no data
David Bell	Chief Corporate Development	21.8yrs	no data	0.0029% € 202.9k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	no data	0.00078% € 53.8k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	no data	no data
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	no data	no data
Sergio Adell	President of Commercial Tech Support	5.8yrs	no data	no data
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	no data	no data
Daniel Coit	Chief Industrial Services Officer	5.8yrs	no data	no data

6.8yrs

Average Tenure

57.5yo

Average Age

Experienced Management: GRFE's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jose Ignacio Abia Buenache	CEO & Director	less than a year	no data	0.014% € 942.5k
Víctor Grifols Deu	Executive Director	8.5yrs	€1.04m	0.016% € 1.1m
Iñigo Mardones	Independent Director	9.5yrs	€150.00k	no data
Thomas Glanzmann	Non-Executive Chairman	18.6yrs	€1.90m	0.029% € 2.0m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	no data
Raimon Grifols Roura	Vice-Chairman	9.5yrs	€1.04m	0.0060% € 417.4k
Tomas Daga Gelabert	Independent External Director	24.6yrs	no data	0.045% € 3.1m
Albert Coma-Cros	Proprietary Director	less than a year	no data	0.0097% € 670.0k
Enriqueta Font	Independent Director	5.5yrs	€125.00k	no data
Montserrat Abellana	Lead Independent Director	2.4yrs	€63.00k	no data
Susana Gonzalez Rodriguez	Independent Director	2.4yrs	€63.00k	no data
Anne-Catherine Berner	Independent Director	less than a year	no data	no data

7.0yrs

Average Tenure

60yo

Average Age

Experienced Board: GRFE's board of directors are considered experienced (7 years average tenure).

Grifols Management

Management criteria checks 2/4

Key information

Recent management updates

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols Announces Executive Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

First quarter 2024 earnings released

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 20% undervalued after recent price drop

Full year 2023 earnings released

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols Announces Executive Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Third quarter 2023 earnings released

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 17%

Full year 2022 earnings released

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Insufficient new directors

Now 22% undervalued after recent price drop

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age